DAPACONAZOLE

Investigational

Details

Stereochemistry	RACEMIC
Molecular Formula	C19H15Cl2F3N2O
Molecular Weight	415.236
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC(F)(F)C1=CC=C(COC(CN2C=CN=C2)C3=C(Cl)C=C(Cl)C=C3)C=C1

InChI

InChIKey=FUAHXHWSMYFWGE-UHFFFAOYSA-N

InChI=1S/C19H15Cl2F3N2O/c20-15-5-6-16(17(21)9-15)18(10-26-8-7-25-12-26)27-11-13-1-3-14(4-2-13)19(22,23)24/h1-9,12,18H,10-11H2

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26419668 | https://patents.google.com/patent/US20120196908A1/en | https://clinicaltrials.gov/ct2/show/NCT03320486

Dapaconazole is an imidazolic compound developed by Biolab Sanus Farmaceutica for the treatment of fungal infections. Dapaconazole was investigated in several clinical trials. In patients with Pityriasis versicolor infections, dapaconazole demonstrated a good safety profile and was non-inferior to ketoconazole when topically applied as a 2% cream at a dose of 20 mg/day for 28 consecutive days. The drug is being investigated in phase 3 clinical trial for the treatment of Tinea Pedis.

Approval Year

Name

Type

Language

dapaconazole [INN]

Preferred Name

English

DAPACONAZOLE

Official Name

English

1-(RAC-2-(2,4-DICHLOROPHENYL)-2-((4-(TRIFLUOROMETHYL)PHENYL)METHOXY)ETHYL)-1H-IMIDAZOLE

Systematic Name

English

Dapaconazole [WHO-DD]

Common Name

English

1H-IMIDAZOLE, 1-(2-(2,4-DICHLOROPHENYL)-2-((4-(TRIFLUOROMETHYL)PHENYL)METHOXY)ETHYL)-

Systematic Name

English

Code System Code Type Description

SMS_ID

300000036997